News | January 13, 2022
Normalised quarter with impending margin pressure: ICICI Direct
ICICI Direct gives a preview on the earnings narrative for Q3FY22
ICICI Direct gives a preview on the earnings narrative for Q3FY22
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Flattish volume growth and subdued new launches were key factors for last month
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Subscribe To Our Newsletter & Stay Updated
